This announcement is a separate document:
四川百利天恒药业股份有限公司自愿披露关于BL-B01D1（EGFR×HER3-ADC）用于局部晚期或转移性三阴乳腺癌III期临床试验完成首例受试者入组的公告
Sichuan Baili Tianheng Pharmaceutical Co., Ltd. voluntarily disclosed an announcement regarding the completion of the first patient enrollment in Phase III clinical trial of BL-B01D1 (EGFR x HER3-ADC) for locally advanced or metastatic triple-negative breast cancer.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.